HEMGENIX FUNDAMENTALS EXPLAINED

Number of eligible people: CDEC reviewed the uncertainty in the quantity of patients with moderately intense to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Scientific gurus consulted by CADTH indicated that some patients who are labeled as getting mild or moderate condition may have a serious bleeding phenotype, which wo